Equity Overview
Price & Market Data
Price: $12.20
Daily Change: -$0.15 / 1.23%
Daily Range: $12.03 - $12.75
Market Cap: $1,643,060,480
Daily Volume: 1,642,175
Performance Metrics
1 Week: -3.71%
1 Month: -2.48%
3 Months: 52.50%
6 Months: 80.74%
1 Year: 402.1%
YTD: 37.70%
Company Details
Employees: 155
Sector: Health technology
Industry: Biotechnology
Country:
Details
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.